MM_Hub: CONGRESS|#EHA 2021|Afsaneh M. Shariatpanahi, OS/PFS risk score (Inflammation score) based on expression of selective genes, achieved the best outcome & superior performance compared to ISS& R-ISS. #mmsm, #myeloma, Terry Fox Laboratory.

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA 2021|Afsaneh M. Shariatpanahi, OS/PFS risk score (Inflammation score) based on expression of selective genes, achieved the best outcome & superior performance compared to ISS& R-ISS. #mmsm, #myeloma, Terry Fox Laboratory....

MM_Hub: CONGRESS|#EHA2021| @Aisha_Jibril_ discussed that MM releases mtDNA into the microenvironment & mtDAMPs promotes progression of MM via a pro-inflammatory BMM. Targeting potential receptor signalling pathways as a therapeutic intervention for MM was proposed, #mmsm, #myeloma,@NNUH

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA2021| @Aisha_Jibril_ discussed that MM releases mtDNA into the microenvironment & mtDAMPs promotes progression of MM via a pro-inflammatory BMM. Targeting potential receptor signalling pathways as a therapeutic intervention for MM was proposed, #mmsm,...

MM_Hub: CONGRESS|#EHA 2021|Mounzer Agha presented initial results of CARTITUDE-2 for cilta-cel safety & efficacy for pts with multiple myeloma. Pts receiving 1–3 prior lines of therapy had early & deep responses with manageable safety.#mmsm, #myeloma, @PittTweet,

by | Jun 11, 2021 | Twitter

CONGRESS|#EHA 2021|Mounzer Agha presented initial results of CARTITUDE-2 for cilta-cel safety & efficacy for pts with multiple myeloma. Pts receiving 1–3 prior lines of therapy had early & deep responses with manageable safety.#mmsm, #myeloma, @PittTweet,...

MM_Hub: CONGRESS | #ASCO21 | @NBahlis presents the initial results of elranatamab, a novel BCMA/CD3 bispecific antibody, in triple-class exposed patients. Deep and durable responses were achieved even in BCMA-exposed pts. Of note, pts did not receive premedication for CRS. #mmsm

by | Jun 11, 2021 | Twitter

CONGRESS | #ASCO21 | @NBahlis presents the initial results of elranatamab, a novel BCMA/CD3 bispecific antibody, in triple-class exposed patients. Deep and durable responses were achieved even in BCMA-exposed pts. Of note, pts did not receive premedication for CRS....